Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Exelixis Puts '184 Back in Spotlight With "Dramatic" Prostate Cancer Results

This article was originally published in The Pink Sheet Daily

Executive Summary

In interim Phase II data, the unpartnered drug reverses bone lesions in metastatic prostate cancer patients.

You may also be interested in...



Cometriq Thyroid Approval May Open Door For Use In Prostate Cancer

As cabozantinib wins FDA approval for the rare medullary thyroid cancer, Exelixis stresses its broader development program in other tumor types, notably prostate cancer. The company is likely to submit prostate cancer data to compendia, which if successful could enable reimbursement for the off-label use.

Will Exelixis’ Cabozantinib Miss The Boat In Prostate Cancer?

Exelixis says one pain study may do it for approval, despite losing an SPA with FDA and the agency’s preference for an overall survival endpoint.

Exelixis Explains Cabozantinib Thyroid Cancer Delay As Prostate Program Takes Shape

The results from the event-driven pivotal trial of Exelixis Inc.’s cabozantinib in medullary thyroid cancer will be delayed by three more months, but there is a good chance for a positive outcome.

Related Content

Topics

UsernamePublicRestriction

Register

PS071462

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel